Allergan Posurdex NDA by year end?
This article was originally published in Pharmaceutical Approvals Monthly
Allergan plans to submit a macular edema NDA for Posurdex (dexamethasone) in late 2006 or early 2007, the company says May 3. The firm is highlighting less frequent dosing it says is possible with the extended-release drug delivery technology used in the proprietary dexamethasone formulation (1Pharmaceutical Approvals Monthly February 2006, p. 16). Allergan notes it also has completed preclinical studies of Posurdex in combination with anti-VEGF agents for treatment of macular degeneration. Genentech's VEGF agent Lucentis (ranibizumab) has a June 29 priority review user fee date for macular degeneration (2Pharmaceutical Approvals Monthly March 2006, In Brief)...
You may also be interested in...
Allergan and partner Sirna hope to advance novel RNAi-based retinal disease agent Sirna-027 into Phase II trials for macular degeneration this year, according to Allergan
US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.